BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11776818)

  • 1. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
    Tan Y; Zhang P; Zheng C
    Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
    Li R; Li R; Wang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
    Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S
    Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The value of serum tumor marker in the diagnosis of lung cancer].
    Shi GL; Hu XL; Yue SD; Song CX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis.
    Takahashi H; Kurishima K; Ishikawa H; Kagohashi K; Kawaguchi M; Satoh H
    Anticancer Res; 2010 Sep; 30(9):3833-7. PubMed ID: 20944179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
    Pavićević R; Milicić J; Bubanović G; Supe S
    Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of the novel tumor marker CYFRA21-1 in patients with esophageal cancer].
    Wang T; Zhang W; Liu Y
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1390-1. PubMed ID: 11930636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
    Ebert W; Muley T
    Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
    Hang ZQ; Zheng MF; Huang JH
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Yamamoto N; Iida T
    Anticancer Res; 2003; 23(3C):2869-74. PubMed ID: 12926125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of serum CK19-2G2 and Cyfra21-1 protein and comparison of their diagnostic value for lung cancer].
    Gao J; Wang H; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):930-2. PubMed ID: 19173996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer].
    Mroczko B; Szmitkowski M; Czygier M
    Przegl Lek; 1999; 56(12):763-6. PubMed ID: 10789186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between N-linked oligosaccharide chains of human serum immunoglobulin G and serum tumor markers with non-small cell lung cancer progression.
    Kanoh Y; Ohara T; Mashiko T; Abe T; Masuda N; Akahoshi T
    Anticancer Res; 2006; 26(6B):4293-7. PubMed ID: 17201147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
    Muley T; Dienemann H; Ebert W
    Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.